– Palleon and Henlius to co-develop Bifunctional HER2-Sialidase and a second bifunctional sialidase to be jointly designed – – Henlius received exclusive license for two products in China (including Hong Kong, Macau, and Taiwan); Palleon retains all other global rights – – Palleon receives upfront payment and is eligible for up to $196.5 million in … [Read more…]
Phase 1 Clinical Trial in Patients with Advanced B-Cell Malignancies Expected to Begin in the Second Half of 2022 NEW YORK–(BUSINESS WIRE)–Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application … [Read more…]
Positive Phase 1 results reported at the American Association for Thoracic Surgery (AATS) and the American Society of Gene and Cell Therapy (ASGCT) revealed XC001 is well tolerated at all dose levels Phase I data support XC001 therapeutic effect and potential dose response Topline Phase 2 data readout expected in February 2023 with interim results … [Read more…]
NASHVILLE, Tenn.–(BUSINESS WIRE)–Mountain Group Partners (“Mountain Group” or the “Firm”), a Nashville-based venture capital firm, announced the closing of an above target amount of $128 million in its third fund (“MGP Fund III”). Mountain Group will continue its strategy of investing in early-stage companies within human and animal life sciences and disruptive technologies. “We are … [Read more…]
Dr. Huang brings more than 30 years of biopharma experience, most recently as Chief Executive Officer and President of Flagship Pioneering start-up Cygnal Therapeutics Dunad appoints new CEO as company establishes U.S. operations, continues to expand its platform based on novel insights into covalent chemistry and build its internal drug discovery programs CAMBRIDGE, England–(BUSINESS WIRE)–Dunad … [Read more…]
Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful results Priovant is developing brepocitinib in severe autoimmune diseases with few approved therapies and where dual inhibition of TYK2 and JAK1 may provide greater efficacy than inhibiting … [Read more…]
– Pivotal ZUMA-5 Study Demonstrates Overall Response Rate of 91% and a Complete Response rate of 77% in Patients Who Received Yescarta After Three or More Lines of Therapy – – Kite’s Third Approved Cell Therapy Indication in Europe – SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Commission … [Read more…]
In response to strong results, the Agency has extended DNA Script’s contract SOUTH SAN FRANCISCO, Calif. & PARIS–(BUSINESS WIRE)–#DNASynthesis–DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has announced the first successful qPCR assays using primers and probes synthesized by a customer via enzymatic synthesis using the company’s SYNTAX System … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global Wearable Medical Devices Market to 2027” report has been added to ResearchAndMarkets.com’s offering. Wearable medical devices are the type of handheld monitoring tools which are used in monitoring and identification of diseases. The demand for wearable medical devices are continuously increasing in the market, where disposable income, innovations, and technological advancements are … [Read more…]
ROUEN, France–(BUSINESS WIRE)–This strategic alliance formed by UbiPharm and Imperial, both significant logistics and distribution players in the healthcare industry in Africa, will provide complementary continental route-to-market solutions to healthcare principals and clients, leveraging best-in-class operations and commercial services. While UbiPharm and Imperial will each maintain their individual business autonomies, the strategic alliance will drive … [Read more…]
